GH SecretagoguesLimited ResearchResearch OnlyB

MK-677

Ibutamoren

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts may use modeled aggregates when live snapshots are unavailable.

Studies cited
6
Research grade
B
Experience
68

Overall check-ins

Activity
76

Trackers & reports

Typical Dose

10–25 mg daily

Route

Oral

Cycle

8–16 week cycles

Storage

Room Temperature

What is MK-677?

Oral ghrelin receptor agonist used in GH-axis research.

Research Indications

Growth Hormone SupportMost Effective

Stimulates natural GH release through pituitary signaling pathways

Body CompositionEffective

Associated with increased lean mass and reduced body fat

Recovery & RepairEffective

Supports tissue repair and recovery from exercise or injury

Sleep QualityModerate

Some protocols show improvements in slow-wave and restorative sleep

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting Dose100 mcgOnce dailySubcutaneous injection
Standard Dose200 mcgTwice dailySubcutaneous injection
Maximum Dose300 mcg3x dailySubcutaneous injection

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Insulin / IGF-1Monitor
CorticosteroidsCaution
Thyroid HormonesMonitor
BPC-157Compatible
TB-500Compatible
Ipamorelin + CJC-1295 (synergistic combo)Compatible
Somatostatin AnalogsAvoid

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove MK-677 vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Improved sleep quality may begin. Mild water retention possible initially.

Week 2–4

Deeper sleep, improved recovery. Appetite may increase slightly.

Week 4–8

Noticeable improvements in body composition, energy, and recovery speed.

Week 8–12

Skin quality improvements, reduced body fat, increased lean mass becoming visible.

Week 12+

Sustained improvements in body composition, strength, and overall vitality.

Side Effects & Safety

  • Water retention and mild bloating, especially early in protocol
  • Increased appetite (particularly with GHRP compounds)
  • Flushing or warmth at injection site
  • Tingling or numbness (carpal tunnel-like symptoms at higher doses)
  • Fatigue or lethargy if dosed at suboptimal times
  • Cortisol and prolactin elevation possible (especially GHRP-6)
  • Rare: Elevated blood glucose — monitor if diabetic or pre-diabetic

FDA Status & Regulatory Info

Research Only

Oral ghrelin receptor agonist used in GH-axis research.

Rx Required: No
503A Ban: No
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 503 users report

Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.

503 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 34% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
-122
Digestive comfort
-163
Skin appearance
-123
Appetite control
-140
Energy
-97

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
-26
Flushing
-83
Headache
-158
GI discomfort
-145
Dizziness
-98

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.2–5 mg

0.2–0.4 mg
10
0.4–0.6 mg
12
0.6–1 mg
17
1–2 mg
9
2–3 mg
10
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking20side effects13mk-67711

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 111 repeat reporters

Share Your Experience

Rate MK-677 in the PeptIQ app and help the community make informed decisions.

Research References (5)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    MK-677, an orally active growth hormone secretagogue: effects on body composition

    Murphy MG, Plunkett LM, Gertz BJ, et al. J Clin Endocrinol Metab. 1998

    Source
    Wiki study page →
  2. PubMed

    Two-year treatment with ibutamoren increases bone mineral density, body composition, and quality of life

    Nass R, Pezzoli SS, Oliveri MC, et al. J Clin Endocrinol Metab. 2008

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    Ibutamoren (MK-677) studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism

    Murphy MG, Plunkett LM, Gertz BJ, et al. The Journal of clinical endocrinology and metabolism. 1998

    Source
    Wiki study page →
  5. PubMed

    Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control

    Philip M, Karakka Kal AK, Subhahar MB, et al. Rapid communications in mass spectrometry : RCM. 2022

    Source
    Wiki study page →

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your MK-677 protocol in PeptIQ

Turn this MK-677 guide into a living protocol — doses, vials, and history in one place.

Track MK-677Open web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Half-Life
~24 hours
Route
Oral
Availability
Research only
Rx Required
No
503A Ban
No
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss MK-677 with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ